Stephen Farr

Stephen Farr Overview

  • Investor Type
  • Angel
  • Investments
  • 1
  • Portfolio
  • 1

Stephen Farr General Information

Description

Dr. Stephen Farr is a Co-Founder and currently serves as the Chief Executive Officer, President and a member of the board of directors of Zogenix, a company he co-founded in 2006. He is a Board member of Flow Pharma. He has been actively involved in the private and public financing of Zogenix, raising in excess of $250 million, and leading the company through an IPO in November 2010. He is responsible for Research and Development, Clinical Development, Regulatory Affairs, Quality and Manufacturing Development functions. In this role, he has overseen the development and NDA approval of Sumavel DosePro, a first-of-its-kind needle-free delivery system for subcutaneous sumatriptan, the Phase 2/3 development of Zohydro, an extended-release oral formulation of single-entity hydrocodone, and in developing the early stage pipeline of products based upon the DosePro technology. From 1995 to August 2006, he held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. For 7 years, he led the inhaled insulin collaboration with Novo Nordisk and took the product from laboratory proof-of-concept to international Phase 3 clinical studies in Type 1 and Type 2 diabetes. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, he was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He has widely published on advanced drug delivery and was made a Fellow of the American Association of Pharmaceutical Scientists in 1998. He is an Adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University and also serves on the board of ICVRx, a start-up, clinical stage company focused on new treatments for the treatment of medically refractory epilepsy. He also serves as Board Member at Cerebral Therapeutics. Dr. Farr is a Member of the Royal Pharmaceutical Society (registered pharmacist in the United Kingdom) and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.

Contact Information

Primary Investor Type
Angel (individual)

Stephen Farr Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
0000 000000 00000 (00000 Biotechnology Product Development 0000000 0000 00.0
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Stephen Farr Team (1)

Name Title Deals Funds Boards Office
Stephen Farr Ph.D Angel Investor 0 0 San Diego, CA